Truist raised the firm’s price target on Nevro to $23 from $22 and keeps a Hold rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO:
- Nevro downgraded to Hold at Canaccord on increased competition
- Nevro downgraded to Hold from Buy at Canaccord
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Nevro Announces Acquisition of Vyrsa™ Technologies
- Nevro’s SCS system delivers long-term relief with spinal cord stimulation